DNLI
Price
$11.60
Change
-$0.18 (-1.53%)
Updated
Apr 7 closing price
Capitalization
1.68B
35 days until earnings call
OCUL
Price
$6.30
Change
-$0.06 (-0.94%)
Updated
Apr 7 closing price
Capitalization
1B
34 days until earnings call
Ad is loading...

DNLI vs OCUL

Header iconDNLI vs OCUL Comparison
Open Charts DNLI vs OCULBanner chart's image
Denali Therapeutics
Price$11.60
Change-$0.18 (-1.53%)
Volume$1.71M
Capitalization1.68B
Ocular Therapeutix
Price$6.30
Change-$0.06 (-0.94%)
Volume$2.33M
Capitalization1B
DNLI vs OCUL Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. OCUL commentary
Apr 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and OCUL is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 08, 2025
Stock price -- (DNLI: $11.78 vs. OCUL: $6.36)
Brand notoriety: DNLI and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 126% vs. OCUL: 196%
Market capitalization -- DNLI: $1.68B vs. OCUL: $1B
DNLI [@Biotechnology] is valued at $1.68B. OCUL’s [@Biotechnology] market capitalization is $1B. The market cap for tickers in the [@Biotechnology] industry ranges from $283.55B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, OCUL is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 5 TA indicator(s) are bullish while OCUL’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 5 bullish, 3 bearish.
  • OCUL’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than OCUL.

Price Growth

DNLI (@Biotechnology) experienced а -20.30% price change this week, while OCUL (@Biotechnology) price change was -16.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.12%. For the same industry, the average monthly price growth was -17.78%, and the average quarterly price growth was -18.34%.

Reported Earning Dates

DNLI is expected to report earnings on May 13, 2025.

OCUL is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (-9.12% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($1.68B) has a higher market cap than OCUL($1B). OCUL YTD gains are higher at: -25.585 vs. DNLI (-42.198). OCUL has higher annual earnings (EBITDA): -176.14M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. OCUL (392M). DNLI has less debt than OCUL: DNLI (48.7M) vs OCUL (75.8M). OCUL has higher revenues than DNLI: OCUL (63.7M) vs DNLI (0).
DNLIOCULDNLI / OCUL
Capitalization1.68B1B168%
EBITDA-492.89M-176.14M280%
Gain YTD-42.198-25.585165%
P/E RatioN/AN/A-
Revenue063.7M-
Total Cash832M392M212%
Total Debt48.7M75.8M64%
FUNDAMENTALS RATINGS
DNLI vs OCUL: Fundamental Ratings
DNLI
OCUL
OUTLOOK RATING
1..100
6718
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
48
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9598
PRICE GROWTH RATING
1..100
9062
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (48) in the Pharmaceuticals Other industry is somewhat better than the same rating for DNLI (94) in the Biotechnology industry. This means that OCUL’s stock grew somewhat faster than DNLI’s over the last 12 months.

OCUL's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as DNLI (100) in the Biotechnology industry. This means that OCUL’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (95) in the Biotechnology industry is in the same range as OCUL (98) in the Pharmaceuticals Other industry. This means that DNLI’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Price Growth Rating (62) in the Pharmaceuticals Other industry is in the same range as DNLI (90) in the Biotechnology industry. This means that OCUL’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as OCUL (100) in the Pharmaceuticals Other industry. This means that DNLI’s stock grew similarly to OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIOCUL
RSI
ODDS (%)
Bullish Trend 7 days ago
77%
Bullish Trend 7 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 7 days ago
76%
Bullish Trend 7 days ago
84%
Momentum
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 7 days ago
82%
MACD
ODDS (%)
Bullish Trend 7 days ago
84%
Bearish Trend 7 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 7 days ago
82%
Bearish Trend 7 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
85%
Bearish Trend 7 days ago
90%
Advances
ODDS (%)
Bullish Trend 11 days ago
79%
Bullish Trend 15 days ago
80%
Declines
ODDS (%)
Bearish Trend 7 days ago
79%
Bearish Trend 7 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
73%
Bullish Trend 7 days ago
81%
Aroon
ODDS (%)
Bearish Trend 7 days ago
83%
Bearish Trend 7 days ago
90%
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME23.492.39
+11.33%
GameStop Corp
SPY505.28-31.42
-5.85%
SPDR® S&P 500® ETF Trust
BTC.X78214.484000-5290.312500
-6.34%
Bitcoin cryptocurrency
AAPL188.38-14.81
-7.29%
Apple
TSLA239.43-27.85
-10.42%
Tesla

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with RCKT. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-7.90%
RCKT - DNLI
55%
Loosely correlated
-7.91%
BEAM - DNLI
55%
Loosely correlated
-7.23%
ARWR - DNLI
55%
Loosely correlated
-11.44%
NTLA - DNLI
53%
Loosely correlated
-3.77%
RGNX - DNLI
52%
Loosely correlated
-5.70%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
-9.21%
EYPT - OCUL
54%
Loosely correlated
-7.62%
DNLI - OCUL
43%
Loosely correlated
-7.90%
BHVN - OCUL
42%
Loosely correlated
-9.54%
APGE - OCUL
41%
Loosely correlated
-7.63%
KRYS - OCUL
41%
Loosely correlated
-3.83%
More